Exicure faces a precarious outlook as it operates without any revenue generation, evidenced by multiple quarters of zero top-line growth. The company's reliance on a non-productive cost structure, with quarterly operating expenses consistently exceeding $1.5 m...
Price trend, volume and key moving averages
Trailing total returns as of 9/25/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 14, 2026 | -$0.18+99.0% vs -$18.60 | — vs $2M |
Q2 2026 May 29, 2026 | -$0.29+98.4% vs -$18.60 | — vs $2M |
Q2 2026 Mar 25, 2026 | -$0.46+51.6% vs -$0.95 | $22M+458.3% vs $4M |
Q4 2025 Nov 7, 2025 | -$0.39+91.3% vs -$4.50 | $2M-48.3% vs $4M |
WILMINGTON, Del., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that, on September 10, 2026, it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company an extension through December 2, 2026 to regain compliance with Nasdaq Listing Rule 5550(b)(1).
WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (“GPCR Therapeutics”) during August 2026 in settlement of a $1.0 million clinical milestone payment obligation under the parties' License and Collaboration Agreement.
WILMINGTON, Del., June 30, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) ("Exicure" or the "Company") today announced changes to its Board of Directors and Board committees following actions approved by the Company's Board of Directors at its special meeting held on June 24, 2026.
Benchmark XCUR against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Exicure, Inc. (XCUR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.23 | $7.84M | -1.56 | -100% | — | -92.47% | — | |
| $18.39 | $1.94B | -2.58 | 15.58% | -6.93% | -9.96% | — | |
| $66.07 | $9.31B | -5415.57 | 23258.15% | -47.79% | -60.05% | — | |
| $12.16 | $1.36B | -3.19 | 16.92% | -672.16% | -57.79% | — | |
| $24.66 | $2.54B | -30.44 | 120.01% | -54.75% | -7.7% | — | |
| $2.75 | $422.02M | -1.53 | 25.39% | -157.32% | -196.63% | — |
Exicure, Inc. (XCUR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Exicure, Inc. (XCUR) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jun 30, 2026·SEC
Jun 1, 2026·SEC
Apr 10, 2026·SEC
Get notified when XCUR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Exicure, Inc. (XCUR) stock FAQ — growth, dividends, profitability & financials explained
Exicure, Inc. (XCUR) saw revenue decline by 100.0% over the past year.
Exicure, Inc. (XCUR) reported a net loss of $8.3M for fiscal year 2025.
Exicure, Inc. (XCUR) has a return on equity (ROE) of -92.5%. Negative ROE indicates the company is unprofitable.
Exicure, Inc. (XCUR) had negative free cash flow of $6.4M in fiscal year 2025, likely due to heavy capital investments.
